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Abstract 
Pneumocystis pneumonia (PCP) is a serious infection caused by a fungus called 
Pneumocystis jiroveci. The fungus is very common and healthy immune system can 
easily control it. However infection may occurs in people with weakened immune 
systems, such as those withHIV/AIDS, bone marrow and organ transplantation. 
Pneumocystis cariniipneumonia,the most common presenting manifestation of the 
acquired immunodeficiency syndrome(AIDS),is a major and recurring cause of morbidity 
and mortality for persons infected with the immunodeficiency virus(HIV).PCP is still the 
most common opportunistic infection in people with HIV/AIDS. Before HIVmedication 
was available, PCP occurred in 70% to 80% of HIV-positive people. The number of 
cases has decreased a great deal. This is due to highly active antiretroviral therapy 
(HAART) and PCP-preventive drugs. About 9% of patients with HIV/AIDS who are 
hospitalized have PCP.PCP are reported with high frequency in HIV-infected children in 
Africa. The mortality rate is between 5% and 40%, even with treatment. Clinical 
manifestations of PCP include fever, non-productive cough, shortness of breath, weight 
loss and night sweats, and pneumothorax is a well-known complication of 
PCPDiagnostic methods of choice include sputum induction and bronchoalveolarlavage 
(BAL),Gallium 67scans,histological identification and by PCR. Drug of choice for 
treatment and prophylaxis is trimethoprim-sulfamethoxazole, and corticosteroid as an 
adjunctive therapy. 
